Navigation Links
Ulcerative in Medical Technology

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Lar...

Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis

-- Phase 1 RDEA119 data expected in second half of 2008 -- -- Presentation at the Seventh Annual JMP Securities Research Conference on May 21st canceled; webcast of corporate update scheduled during Ardea's Annual Stockholder Meeting on May 22nd at 9:30 a.m. PT -- SAN DIEGO, May...

Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis

4.8 g/day dose using investigational 800 mg tablet demonstrated efficacy and was well tolerated in ASCEND III study SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- In a study presented today at the 39th Annual Digestive Disease Week (DDW) meeting in San Diego, California, 70 percent ...

New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease

A Separate Retrospective Analysis of US Employer Claims Suggests a Benefit of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among Employees with Inflammatory Bowel Disease SAN DIEGO, May 20 /PRNewswire/ -- Data from a new analysis of the Active Ulcerative Colitis Tri...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- A post hoc analysis showing time to symptom resolution data from a study (study 302) of Shire plc's (LSE: SHP, Nasdaq: SHPGY) ulcerative colitis (UC) drug, LIALDA(TM), will be presented today at Digestive Disease Week (DDW). Study 302 (further referr...

Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis

Presentation of Phase 1 Clinical Data of MDX-1100 at Digestive Disease Week 2008 PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today that it has initiated the Phase 2 clinical development program of MDX-1100, a fully h...

Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis

Findings reinforce the benefits of Asacol for ulcerative colitis patients AVENTURA, Fla., Dec. 5 /PRNewswire/ -- Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an eff...

New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients

Symptom resolution results based on stringent endpoint of clinical remission is more clinically relevant, beneficial to patients PHILADELPHIA, Oct. 15 /PRNewswire-FirstCall/ -- An analysis of data to be presented tomorrow at the American College of Gastroenterology (ACG) Annual Scientif...

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients taking once-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroente...

Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up

Separate Survey Underscores Impact of Disease on Work Status and Productivity WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ -- Findings presented today at Digestive Disease Week(R) 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects wi...

Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

LONDON, 2 July 2007: Chi-Med, the Hutchison Whampoa backed pharmaceutical and healthcare Group, today announces positive results for its Phase II proof-of-concept study for HMPL-004 in mild-to-moderate Ulcerative Colitis, a form of inflammatory bowel disease. The trial met its objectiv...

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa Clinical Trial Results First clinical Results Confirm Potential New Application of Key Product in AM-Pharma's Pipeline BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., the biopharmaceutical company developing novel therapeutics to trea...

Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets

...release tablets, which are indicated for the treatment of moderately active ulcerative colitis (UC), a form of inflammatory bowel disease. UC involves inflammatio...as 79 percent in ASCEND III and 74 percent in ASCEND II. (1,2) About ulcerative Colitis (UC) UC involves inflammation of the lining of the colon and re...

New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease

...for the treatment of moderately to severely active ulcerative colitis, in patients with an inadequate response t...osing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and ...enage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE and azathioprine ...

Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW

...rentiating IBD vs. non-IBD and Crohn's disease vs. ulcerative colitis than using traditional cutoff value analys...tibility. It is estimated that Crohn's disease and ulcerative colitis, the two main types of IBD, together affec...S. The main difference between Crohn's disease and ulcerative colitis is the location and nature of the inflamma...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

...ting patients with Crohn's disease and potentially ulcerative colitis," said Pirow Bekker, M.D., Ph.D., Senior V...inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In prec... prophylactically in models of Crohn's disease and ulcerative colitis. In addition to the ongoing PROTECT-1 cli...

Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis

...100 in a range of inflammatory diseases, including ulcerative colitis in an ongoing companion Phase 2 study." ...MDX-1100 is also being explored as a treatment for ulcerative colitis (UC). A Phase 2 randomized, double-blind, ...ucosal inflammation ascertained by endoscopy. ulcerative colitis is a chronic inflammatory bowel disease ch...

Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments

...y is also looking at Leukotoxin for use in autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, lupus, Crohn's disease and ulcerative colitis. "While there are numerous drug candidates under development for treating various forms of leukemia, Dr. Kachlany's approach to utilizing...

Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease

...ultaneous Studies to Investigate Novel Therapy for ulcerative Colitis and Crohn's Disease OSAKA, Japan, Jan...ogram, will study vedolizumab for the treatment of ulcerative colitis and Crohn's disease, the two main types of...ove the lives of patients with Crohn's disease and ulcerative colitis." Though current IBD treatments have ...

Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects

...flammatory and autoimmune disorders (under review in EU for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis, and in Phase III for ulcerative colitis); Schering-Plough has exclusive marketing rights to golimumab outside the U.S. except in Japan and certain other Asian markets; SAPHRI...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

... many as half a million Americans. People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn's disease is an inflammatory bowel disease (IBD). About CIMZIA (certolizumab pegol) CIMZIA is the only PEGylated anti-TNFa (Tumour ...

Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting

...ed chronic colitic mice. The beneficial effect of RDEA119 exceeded that of Remicade(R) (infliximab), the current standard-of-care for the treatment of ulcerative colitis. "Blocking the MEK1/2 pathway appears to be a promising strategy for treating inflammatory disease, for which a significant unmet medical ne...

New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study

...apy that the FDA has approved for the treatment of ulcerative colitis, a related inflammatory bowel disease, and...osing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and ...itis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. ...

CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients

... many as half a million Americans. People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives. Together with ulcerative colitis, Crohn's disease is an inflammatory bowel disease (IBD). About CIMZIA (certolizumab pegol) CIMZIA is the only PEGylated anti-TNFa (Tumour ...

New Genes Found for Inflammatory Bowel Disease in Children

...ase, which can affect any part of the gastrointestinal tract, and half have ulcerative colitis, which is limited to the large intestine. IBD that begins in chil...omized to each patient." The study team also found an association between ulcerative colitis and genes on the major histocompatiblity complex (MHC) on chromosom...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

...or equal to one percent with PEGINTRON(TM): Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...

Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City

...-1100 represents a breakthrough mechanism of action for inflammatory disease and is being investigated in separate Phase 2 proof-of-concept trials for ulcerative colitis and rheumatoid arthritis. Interim data from these trials are expected in 2009. -- MDX-1401 is a fully human antibody that targets CD30, a me...

Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis

... a Phase IIb study for patients with moderate-to-severe, steroid-refractory ulcerative colitis (UC) in April 2007. "The initiation of this proof-of-concept stud...is being assessed as a treatment for moderate-to-severe, steroid-refractory ulcerative colitis (UC). The second program is studying Simulect as a treatment for no...

FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis

...lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. The world leader in monoclonal antibody production and technology, Centocor has brought critical b...

ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease

... the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in models of Crohn's d...

Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis

...lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis. The world leader in monoclonal antibody production and technology, Centocor has brought critical b...

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment

...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...

Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...

Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)

...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting

...than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmo...

Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients

...to accumulate in the GI tract, liver and bone in animals, the clinical significance in humans is unknown. -- Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were not included in FOSRENOL clinical studies. Caution should be used in patients with these...
Other Tags
(Date:7/9/2014)... concern about the prevalence of antibiotic-resistant illness, Case ... pathway to disabling disease: blocking bacteria,s access to ... how bacterial siderophore, a small molecule, captures iron ... growth as well as how the body ... Their findings appear in a recent edition of ...
(Date:7/9/2014)... global census of Adlie penguins shows that the ... percent larger than previously estimated. Adlie penguins have ... monitor and understand the effects of climate change ... using high-resolution satellite imagery, researchers from Stony Brook ... new method that permits regular monitoring of Adlie ...
(Date:7/9/2014)... laboratory testing, countless measurement results accrue. To completely ... extremely time consuming. In fact, researchers in the ... managing data, according to an online survey of ... the Fraunhofer Institute for Applied Information Technology FIT ... that they have no centralized or structured approach ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3Managing the data jungle 2Managing the data jungle 3
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... may smell of flatulence and have a reputation for being ... hydrogen sulfide is now being being found to offer potential ... stroke, heart attacks and dementia. A new compound (AP39), designed ... key to future therapies, by targeting delivery of very small ... inside cells. , Scientists in Exeter have already found ...
(Date:7/9/2014)... and poor printing on prescription labels handed out ... to errors in taking medication, according to new ... (Canadian National Institute for the Blind)., The study, ... , found that labels on prescription medications dispensed ... guidelines for legibility. , By simply following recommended ...
(Date:7/9/2014)... in Western societies. One frequently cited reason is that ... infections than previous generations, thereby delaying maturation of the ... Academy, University of Gothenburg, monitored children until the age ... in relation to allergic disease. All of the children ... half of them on farms that produced milk.,Lower risk ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
Other Contents